Trial Profile
Differences of Functional Changes in Brain by Rivastigmine According to Butyrylcholinesterase Alleles in Alzheimer's Disease Patients(Rivastigmine, Imaging, and BuChE in AD: RIBA)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Rivastigmine (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Acronyms RIBA
- 13 May 2015 Status changed from not yet recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
- 15 Mar 2014 New trial record